Nikolas London Details Cross-Sectional Analysis of anti-VEGF Drugs


Study evaluated trials of aflibercept and ranibizumab in retinal vein occlusion.

Nikolas London, MD, of Retina Consultants San Diego sat down with MD Magazine at the ARVO 2017 meeting in Baltimore, Maryland, to discuss the findings of a cross-sectional analysis his team was presenting. The project looked at a series of major trials on aflibercept and ranibizumab used in patients with branch and central retinal vein occlusion.

London details the nuances of the findings in this video, and the major takeaways: “The bottom line is that all patients seem to do quite well treated with anti-VEGF therapy, regardless of the agent used,” London concluded.

Recent Videos
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
A panel of 3 experts on dry eye
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Viability of Elamipretide for Geographic Atrophy in Dry AMD | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.